Document:

ex10-1.htm

    AGREEMENT

    

          THIS
AGREEMENT ("Agreement") is entered into and is effective as of April 15, 2008,
by and between Jade Art Group, Inc., a Nevada corporation ("JADG") and Richard
E. Khaleel, an individual resident in the State of New York ("Khaleel" or
“Director”).

    

    Preliminary
Statement

    

     JADG desires to retain Mr.
Khaleel, and Mr. Khaleel is willing to serve, as a member of the Board of
Directors of JADG on the terms and subject to the conditions set forth in this
agreement.

    

                   
NOW, THEREFORE, in consideration of the mutual promises and agreements set forth
below, intending to be legally bound, JADG and Mr. Khaleel hereby agree as
follows:

    

    1.  Appointment.  Mr.
Khaleel has agreed to serve as a member of the Board of Directors of JADG,
effective as of the date of his election to the Board by the current Members of
the Board of Directors (the “Election Date”).

    

    Mr.
Khaleel’s appointment to the Board will be announced to the public in a press
release.  The timing and wording of such release shall be approved by
both JADG and Mr. Khaleel, which shall not be unreasonably withheld or
delayed.

    

    2.  Compensation. For the
duties and services to be performed by him under this agreement, JADG will pay
to Mr. Khaleel, and Mr. Khaleel agrees to accept, the compensation described
below in this Section 2.

    

          a.
Director’s Fees.  JADG will pay Mr. Khaleel a director's fee of
$40,000 per annum, payable in equal monthly installments commencing on the
Election Date. This fee represents a retainer for services rendered as a member
of its Board of Directors, and is in addition to any fees to which Mr. Khaleel
may be entitled under guidelines and rules established by JADG from time to time
for compensating non-employee directors for serving on, and attending meetings
of, committees of its Board of Directors and the boards of directors of its
subsidiaries.

     

          b.
Equity Component. In addition to the cash fee(s) described in subsection (a), on
the Election Date and subject to the provisions hereof JADG will grant Mr.
Khaleel non-qualified options to purchase 100,000 shares of JADG common stock.
The exercise price of these non-qualified options will be the closing sales
price of a share of JADG common stock on the OTC Bulletin Board on the Election
Date.  Options to purchase 33,333 shares may be exercised immediately;
options to purchase an additional 33,333 shares may be exercised commencing
April 15, 2009, and options to purchase the remaining 33,334 shares may be
exercised commencing April 15, 2010, provided that all outstanding and
unexercised options shall expire on the date that Mr. Khaleel is no longer
serving as a member of the Board of Directors of JADG or otherwise engaged by
JADG to provide services to JADG. Subject to the foregoing provisions, the
options may be exercised until April 15, 2018, at which time any such options
that have not been exercised shall automatically expire.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

     3.  Expenses. JADG will
reimburse Mr. Khaleel for reasonable expenses incurred by him in furtherance of
his performance of duties hereunder, provided that such expenses are
substantiated in accordance with JADG policies applicable to members of its
Board of Directors.

    

    4.  Fringe and Medical
Benefits. Mr. Khaleel may participate in any of JADG's medical, dental
and other benefit programs as are available to non-employee members of its
Board.

    

    5.  Confidential Treatment of
Information.   Director shall not, either during or after
the term of this Agreement, directly or indirectly publish or disclose to any
third party any information pertaining in any way to the business of JADG, its
customers or suppliers, which is developed, acquired or derived from association
with JADG, unless JADG gives written authorization to do so. Such information
shall not be used apart from JADG business without written approval of JADG.
Such prohibition against disclosure to others shall not apply to information
after it is clearly disclosed to the public by JADG in writing.

    

    6.  Term and
Termination.  The term of this Agreement will commence on the
Election Date and will remain in effect until Mr. Khaleel is removed, resigns,
or is not reelected as a member of the Board in accordance with JADG’s bylaws.
JADG has no obligation to cause the nomination or recommend the election of Mr.
Khaleel to the Board for any period of time in the future. Upon the termination
of Mr. Khaleel's tenure as a member of the Board, JADG will promptly pay to Mr.
Khaleel, or to his estate if his service is terminated upon his death, all fees
accrued for services rendered as a member of the Board and committees thereof
and expense reimbursements due as of the date of termination.

    

    7.  Indemnification by
JADG.  JADG shall indemnify Mr. Khaleel, as a director of JADG,
to the maximum extent permitted under applicable Nevada law, against all
liabilities and expenses, including amounts paid in satisfaction of judgments,
in compromise, or as fines and penalties, and counsel fees, reasonably incurred
by Mr. Khaleel in connection with the defense or disposition of any civil,
criminal, administrative or investigative action, suit or other proceeding,
whether civil or criminal, in which he may be involved or with which he may be
threatened, while an officer or director of JADG. Expenses (including reasonable
attorney’s fees) incurred by Mr. Khaleel in defending any such action, suit or
other proceeding may be paid by JADG in advance of the final disposition of such
action, suit or proceeding upon receipt of an undertaking by or on behalf of him
to repay such amount if it shall be ultimately determined that he is not
entitled to be indemnified by JADG.  The provisions hereof shall
survive expiration or termination of this Agreement for any reason whatsoever.
In the event of any conflict between the provisions hereof and the
indemnification provisions contained in JADG's articles of incorporation or
bylaws, or in any agreement between JADG and Mr. Khaleel with respect to
indemnification, unless he has explicitly agreed otherwise, Mr. Khaleel will be
given the benefit of the provisions more favorable to him.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    8.  Liability Insurance.
JADG will maintain in effect at all times while Mr. Khaleel continues to serve
as a member of the Board liability insurance provided by a recognized carrier
covering members of its Board with a face amount of no less than $5,000,000 and
deductibles of no more than $150,000.

    

    9.  Non-Exclusive.
Subject to the last sentence of this Section, nothing in this agreement will
prevent Mr. Khaleel (1) from serving as an employee, officer or director of or
providing services to (directly or indirectly) any other company (an
“Engagement”), provided that such Engagement is consistent with Mr. Khaleel's
fiduciary duties to JADG (“Permitted Engagements”), (2) from serving on
voluntary, community service committees and boards, and (3) from owning shares
representing less than 5% of the outstanding equity securities of a company that
is a competitor of JADG (the “Competitor’s Equity”), in which event Mr. Khaleel
shall notify JADG in writing regarding the Competitor’s Equity promptly after he
obtains the Competitor’s Equity.  Mr. Khaleel will comply with and be
bound by JADG's policies, procedures and practices applicable to members of its
Board of Directors from time to time in effect during the term of this
agreement.   Director shall, during the term hereof, (i) advise
JADG prior to entering into any Engagement, and (ii) shall not enter into any
Engagement that is not a Permitted Engagement without the prior written approval
of JADG, which approval shall not be unreasonably withheld.

    

                 
10.  Representations, Warranties
and Covenants of Director. Mr. Khaleel represents and warrants that his
performance of this agreement will not violate any applicable laws or
regulations or conflict with or breach any other agreement to which he is a
party or may be bound. Mr. Khaleel has not, and will not during the term of this
agreement, enter into any oral or written agreement in conflict with any of the
provisions of this agreement. Mr. Khaleel represents and warrants that he is not
bound by any agreements which prohibit or restrict him from: (a) competing with,
or in any way participating in a business that competes with, any former
employer or business of any former employer to the extent that Mr. Khaleel's
performance of his duties under this agreement would be deemed to constitute
such competition; (b) soliciting personnel of a former employer or business to
leave such former employer's employment or to leave such business; or (c)
soliciting customers, suppliers, financing sources or other entities having a
substantial relationship with a former employer or business. Mr. Khaleel shall,
during the term of this Agreement, comply with all applicable listing
requirements, laws and regulations (collectively, the “Laws”) including but not
limited to those Laws applicable to his service as an independent member of the
Board of Directors of JADG, as determined by the Board of Directors under the
independence standards of NASDAQ.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

     11.  Representations and
Warranties of JADG.  JADG has filed all reports required to be
filed by it under the Securities Act and the Securities Exchange Act of 1934, as
amended (the “Exchange
Act”), including pursuant to Section 13(a) or 15(d) thereof, since
January 1, 2007 (the foregoing materials being collectively referred to herein
as the “SEC
Reports”) on a timely basis or has received a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any
such extension.  As of their respective dates, the SEC Reports
complied in all material respects with the requirements of the Securities Act
and the Exchange Act and the rules and regulations of the Securities and
Exchange Commission (the “Commission”) promulgated thereunder, and none of the
SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading.  The financial statements of JADG
included in the SEC Reports complied in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with
respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with generally accepted accounting principles
applied on a consistent basis during the periods involved (“GAAP”), except as may
be otherwise specified in such financial statements or the notes thereto, and
fairly present in all material respects the financial position of JADG and its
consolidated subsidiaries as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, year-end audit adjustments.

    

    There is no claim, action, suit,
proceeding, arbitration, reparation, investigation or hearing, pending or to
JADG’s knowledge, threatened, before any court or governmental, administrative
or other competent authority or private arbitration tribunal, which would likely
have a material adverse effect on the business of JADG; nor are there any facts
known to JADG which would likely be expected to give rise to a claim, action,
suit, proceeding, arbitration, investigation or hearing, which would likely have
a material adverse effect upon the business of JADG.

     

    12. Indemnification by
Director. Director shall indemnify, defend and hold harmless JADG and its
affiliates, officers, directors, employees, agents and representatives
(collectively, “Indemnified Parties”) from and against all loss, liability,
claim, damage or expense (including costs of investigation and reasonable
attorney’s fees) incurred by  such Indemnified Parties, to the extent
arising out of or relating to: (i) any breach of a representation, warranty,
covenant or agreement of Director under this Agreement; or (ii) any fault,
intentional misconduct or wrongful act of Director. The provisions hereof shall
survive expiration or termination of this Agreement for any reason
whatsoever.

    

    13. Governing Law. This
agreement will be governed by, and construed in accordance with the laws of the
State of Delaware, without regard to its choice-of-law principles, and the
United States of America.

    

    14. Notices. All notices
or other communications which are required or permitted hereunder will be in
writing and sufficient if delivered personally or sent by air courier or first
class certified or registered mail, return receipt requested and postage
prepaid, addressed as follows:

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    
      	 
      	
              If
      to Mr. Khaleel, to:

            	
              110
      Riverside Drive Apt 3E

            
	 
      	 
      	
              New
      York, NY 10024

            
	 
      	 
      	 
      
	 
      	
              If
      to JADG, to:

            	
              1330
      Ave. of the Americas, 21st
      Floor

            
	 
      	 
      	
              New
      York, NY 10019

            
	 
      	 
      	
              Attention:
      President

            
	 
      	 
      	 
      
	 
      	
              with
      a copy to:

            	
              White
      and Williams LLP

            
	 
      	 
      	
              1800
      One Liberty Place

            
	 
      	 
      	
              Philadelphia,
      PA 19103-7395

            
	 
      	 
      	
              Attention:
      Chungsheng Lu

            

    

    

    or to
such other address as the party to whom notice is to be given may have furnished
to the other party in writing in accordance herewith. All notices and other
communications given to any party hereto in accordance with the provisions of
this agreement shall be deemed to have been given on the date of delivery if
personally delivered; on the business day after the date when sent if sent by
air courier; and on the third business day after the date when sent if sent by
mail, in each case addressed to such party as provided in this Section or in
accordance with the latest written direction from such party.

    

    15.  Entire Agreement.
This agreement constitutes the sole agreement of the parties and supersedes all
oral negotiations and prior writings, including any and all prior agreements
between Mr. Khaleel and JADG, with respect to the subject matter
hereof.

    

    16. Advice of Counsel.
EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT,
SUCH PARTY HAS HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL
COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS
AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF
THE DRAFTING OR PREPARATION HEREOF.

    

    17.  Counterparts. This
agreement may be executed in one or more counterparts, each of which shall be
deemed an original, but all of which shall constitute one and the same
instrument.

    

    18.  Amendments. No
modification, waiver, amendment, discharge or change of this agreement shall be
valid unless the same is in writing and signed by the party against which the
enforcement of said modification, waiver, amendment, discharge or change is
sought.

    

    19.  Severability. If any
portion of any provision of this agreement, or the application of such provision
or any portion thereof to any person or circumstance shall be held invalid or
unenforceable, the remaining portions of such provision or portion of such
provisions of this agreement or the application of such provision or portion of
such provision as is held invalid or unenforceable to persons or circumstances
other than those to which it is held invalid or unenforceable, shall not be
effected thereby.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    The
parties, by signing below, agree to the terms and conditions set forth in this
agreement.

    

    
      	
              Director

            	
              Jade
      Art Group, Inc.

            
	 
      	 
      
	 
      	 
      
	/s/
      Richard E. Khaleel	
              By:

            	
              /s/
      Hua-Cai Song 

            
	
              Richard
      E. Khaleel

            	 
      	
              Hua-Cai
      Song, Chief Executive Officer

            

    

    

    

     

     

     

    
      6exhibit10-54.htm

    
       

      
        
          EXHIBIT
10.54

        

      

    

    SUPPLY
AGREEMENT FOR ANIMAL HEALTH

    

    

    THIS
AGREEMENT is made and effective this 20th day of  March, 2008, by and
between AMARILLO BIOSCIENCES, INCORPORATED, a Texas corporation with its
principal place of business at 4134 Business Park Drive, Amarillo, Texas 79110
USA (hereinafter “ABI”) and CytoPharm, Inc., (“CYTO”), a corporation, having a
principal place of business at 6 F No. 6, Jungshing Road, Sec. 1, Wugu Shiang,
Taipei County 248, Taiwan, (ABI and CYTO collectively referred to hereinafter as
the “Parties”).

     

    WHEREAS,
ABI has substantial expertise in the production and use of HBL interferon
(hereinafter defined) and has proprietary rights and know-how in the field of
produc­tion, purification, formulation and use of HBL
interferon.

     

    WHEREAS,
ABI and CYTO now desire to promote applications of technology relating to the
oral administration of HBL interferon in the swine, cattle and poultry species
and CYTO desires to use, formulate, test, and market oral dosage forms
of  HBL interferon for treatment of diseases and other healthcare
applications of swine, cattle and poultry in the Territory (hereinafter
defined);

     

    WHEREAS,
CYTO has expressed willingness to pay all costs related to gaining regulatory
approval in Taiwan and China but desires ABI's assistance with study design,
protocol preparation, regulatory affairs and management of clinical
trials.

     

    NOW,
THEREFORE, for and in consideration of the mutual covenants contained herein,
CYTO and ABI agree as follows:

     

    

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    ARTICLE
I

    DEFINITIONS

     

    1.01.    “Agreement” means this Supply
Agreement.

     

    1.02.            “Affiliate” means a
corporation, company, partner­ship, or other business entity which controls
or is controlled by, or is under common control with, the designat­ed
party.  In the case of a corporation, “control” means owner­ship
either directly or indirectly of at least forty percent (40%) of the shares of
stock entitled to vote for the election of directors.  By way of
explanation but not limitation, Cyto Biotech, is an Affiliate of
CYTO.

     

    1.03.            “Anhydrous Crystalline Maltose or
“ACM” means a maltose crystalline powder that is obtained from highly
purified maltose by additional dehydration by heating.

     

    1.04.            “Animal
Dose(s)” means the approved dosage of HBL IFNα in International Units
(IU) per unit dose to be used in the animal species which dosage
shall be determined by the testing to be funded by CYTO.

     

    1.05.            “bulk
HBL interferon” means HBL IFNα provided in a concentrated form for use in
the manufacture of formulations for use in the Licensed
Species.

     

    1.06.            “Commercially Reasonable
Efforts” means, unless the Parties agree otherwise, those efforts
consistent with the exercise of prudent scientific and business judgment, as
applied to other products of similar scientific and commercial potential within
the relevant product lines of the Parties.

     

    1.07             “HBL Agreement” means the Joint
Development and Manufacturing/Supply Agreement by and between HBL and ABI dated
as of March 13, 1992, [as amended by the First Amendment to Joint Development
and Manufacturing/Supply Agreement

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    dated as
of January 17, 1996 and the Addendum to Manufacturing/Supply Agreements dated as
of May 10, 1996 and September 7, 2001].

     

    1.08.            “HBL interferon” means the natural human
interferon-alpha (“IFNα”) used by HBL for the formulation of natural
IFNα-containing formu­lation(s) for use in the treatment of human
renal cell carcinoma and hepatitis B in Japan, presently under the
manufactur­ing and commer­cializing approval of the Ministry of Health
and Welfare in Japan, and which is produced by HBL.  HBL interferon is
provided for use in the manufacture of formulations for use in the Licensed
Species.

     

    1.09.            “Licensed Species” means swine,
cattle and poultry.

     

    1.010.          “Net Sales” means the invoice
amounts actually received for sales of the Product by CYTO, its Affiliates or
sub-licensees in a bona fide arm's length transaction, less the following items,
provided that they are bona fide transactions designed to optimize the sales of
Product (a) cash discounts and trade allowances actually granted, (b) rebates
and charge backs required by Applicable Laws or made pursuant to agreements with
customers, (c) credits or allowances actually granted upon claims, damaged
goods, outdated goods, rejections or returns of such Product, including recalls,
(d) taxes, tariffs and similar obligations, duties or other governmental charges
(other than income taxes and inventory taxes) levied on, absorbed or otherwise
imposed on sales of such Product in the Territory and shown separately on the
invoice, (e) shipping charges, and (f) insurance costs related to
shipping.

     

    1.11.            “Other Interferon” means any
interferon not provided by HBL that is formulated with ACM to treat Licensed
Species.

    
 

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    1.12.            “Product” means a
formulation or composition containing both ACM and HBL IFN, Other Interferon
formulated with ACM, or other products formulated by CYTO based on the above
product and designated for oral use in the Licensed Species.

     

    1.13.            “Technical Information” means
all informa­tion, reports, results, inven­tions, licenses, know-how,
improve­ments, materials, and any other technical and scien­tific data,
specifica­tions and formulae directly related to develop­ment,
regulatory approval, manufacture, testing, use, marketing and/or sale of HBL
interferon, and any non-public information relevant to the business of the
Parties which is necessarily disclosed by one to the other during the Parties'
performance under this Agreement.  “ABI Technical Informa­tion”
refers to Technical Informa­tion originating with ABI or which ABI has
developed or has obtained through its contractual relationships with third
parties including HBL.  “CYTO Technical Informa­tion” refers to
Technical Information originating with CYTO or which CYTO will develop or has
devel­oped or has obtained through its contractual relationships with third
parties.  “Technical Informa­tion” when not other­wise
speci­fied herein means both ABI Technical Information and CYTO
Techni­cal Informa­tion.

     

    1.14.            “Territory” means the countries
of Republic of China (“Taiwan”) and People’s Republic of China
(“China”).

     

     

    ARTICLE
II

    RESEARCH
AND DEVELOPMENT

     

    2.01.    ABI
Obligations.  Subject to the terms and conditions of this
Agreement, ABI shall supply ACM, bulk HBL interferon and ABI Technical
Information for the manufacture, use, formula­tion, testing and/or marketing
of oral dosage forms involving the stabilization and

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    delivery
of HBL IFN in ACM, for use in the Licensed Species in the Territory, exclusively
to CYTO for such use, and to no other persons or entities.  Such oral
dosage forms shall be subject to resale or other distribution by CYTO to other
persons or entities for use, formula­tion, testing, and/or marketing;
provided, however, that CYTO shall not resell or otherwise distribute such oral
dosage forms or HBL interferon and ACM to other persons or entities for
formulation, testing and/or marketing by such other persons or entities without
first obtaining ABI's written approval, which approval shall not be unreasonably
withheld.  ABI shall ­supply ACM and bulk HBL interferon for
delivery to CYTO f.o.b. HBL's manufac­turing facili­ties, or for
delivery at other locations by agreement of the Parties, packaged in bulk, and
such product shall be supplied in response to issu­ance by CYTO of written
purchase orders de­livered to ABI specifying the quantity to be supplied,
along with any special instruc­tions/requests regarding the supply and/or
delivery of the product.

     

    2.02.     CYTO Obligations. CYTO will
use Commercially Reasonable Efforts to timely complete at the sole cost and
expense of CYTO (i) clinical trials and
development of Product for the treatment of the Licensed Species, (ii) animal toxicology and other pre-clinical
studies required for commercial launch of the Product, and
(iii) other tasks supporting
commercialization of the final formulation of the Product.

     

    (a) CYTO
shall use Commercially Reasonable Efforts to timely secure any and all
Governmental Approvals in the Territory and shall own and maintain all
Governmental Approvals and related information as provided herein. The Parties
agree and acknowledge that Governmental Approval for the Product will be sought
in The Territory.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    

     

     

    (b) The
foregoing notwithstanding, it shall be conclusively presumed that CYTO has not
used “Commercially Reasonable Efforts” as to a particular Licensed Species, if
(i) CYTO fails to commence clinical trials for that species within one (1) year
of the Effective Date; or (ii) CYTO fails to achieve commercial sales for that
species within two (2) years of the Effective Date.  If CYTO fails to
enroll a species in a clinical trial within twelve (12) months or fails to
achieve commercial sales for that species within two (2) years, CYTO shall lose
the rights under this Agreement for that particular species, but not for other
species for which CYTO has used Commercial Reasonable Efforts.

     

     

    (c) CYTO
shall maintain records in sufficient detail and in good scientific manner
appropriate for patent and regulatory purposes and shall properly reflect all
work done and results achieved in the performance of its duties hereunder
(including all data in the form required to be maintained under any Applicable
Laws), and any subsequent pre-clinical or clinical studies (the “Clinical
Records”). The Clinical Records generated in the Territory shall be owned by
CYTO and shall be considered Confidential Information of CYTO and
ABI.  ABI may request the Clinical Records, and CYTO shall provide the
Clinical Records to ABI, subject to applicable laws and
regulations.  These records include books, records, reports, research
notes, charts, graphs, comments, computations, analyses, compilations,
recordings, photographs, computer programs and documentation thereof, computer
information storage means, samples of materials and other graphic or written
data generated in connection with CYTO's research and development activities
with respect to the Product.

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    (d) In the
event ABI requests that more than 1,000 pages be copied in connection with the
foregoing, ABI shall reimburse CYTO for CYTO’s actual out of pocket costs for
making copies in excess of 1,000 pages.  ABI shall pay CYTO such
amounts within 30 days following ABI’s receipt of an invoice therefor
accompanied by documentation reasonably supporting such invoice.

     

                    (e) ABI has the right, upon fifteen business days’
prior written notice to CYTO, to review the Clinical Records associated with
CYTO’s activities under this Agreement during normal business hours, and CYTO
shall, subject to Applicable Laws, provide ABI upon request with a copy of all
requested Clinical Records, at ABI’s cost, to the extent reasonably required for
the exercise of ABI's rights under this Agreement. ABI may use the Clinical Records and the summaries thereof for
commercial and regulatory approval purposes. If ABI wants to provide a
non-governmental entity Third Party with the Clinical Records or a summary
thereof or use information contained in such records for a commercial purpose,
ABI may do so as long as the non-governmental entity Third Party agrees to the
Confidentiality provisions of Article VIII.

     

    2.03.    Availability of Resources;
Cooperation. Each Party shall maintain laboratories, offices and/or other
facilities reasonably necessary to carry out the activities to be performed by
such Party hereunder. Upon reasonable advance notice, each Party agrees to make
its employees and non-employee consultants reasonably available at their
respective work locations to consult with the other Party on issues arising
during the collaboration and in connection with any request from any
Governmental Authority, including regulatory, scientific, technical and clinical
testing issues.  Such meeting may be arranged through the internet or
site visit. The meetings should be arranged within 15 working days after the
requests, where feasible. 

     

    2.04.      Reporting Obligations of CYTO.
On or prior to December 31st of each year during the TERM of this Agreement CYTO
shall provide ABI with a report of ongoing development efforts, including a
report of efforts by CYTO with respect to clinical testing, regulatory approval
efforts, marketing/sales strategy, and any other areas into which CYTO's
reasonable business efforts in accordance with this paragraph may reasonably be
categorized. Such report shall be provided in English and shall be accompanied
by samples of labeling, instructions, promotional and other support materials,
if any, developed for CYTO's sales force, patients, physicians, or other outside
parties.

     

    ARTICLE
III

    LICENSE

     

     

    3.01.     License and Supply
Grant.  Subject to the terms of this Agreement and the Existing
Licenses, ABI hereby grants to CYTO:

     

     

    (a) an
exclusive sublicense, under the ABI Technology to use the ABI Technology to
market, advertise, promote, manufacture, offer for sale, sell, and distribute
the Product in the Territory; and

     

    (b) an
exclusive sublicense, under all rights granted to ABI pursuant to the HBL
Agreement to market, advertise, promote, manufacture, offer for sale, sell, and
distribute the Product in the Territory.

     

    3.02.     Restrictions. CYTO shall have
the right to use and sell Product only in the Territory and only for use in the
Licensed Species. . CYTO shall not seek customers, establish any branch or
maintain any distribution depot for Product in any country outside the
Territory. CYTO

    shall not
sell Product to any customer in any country outside the Territory or to any
customer in the Territory if, to the knowledge of CYTO, such customer intends to
resell such Product in any country outside the Territory.

     

    3.03.      Retained
Rights.  ABI retains all rights other than as set forth in this
Agreement to HBL IFN and IFN, including without limitation, the right to test,
develop, license, sublicense, market, distribute or otherwise use IFN and HBL
IFN in the Licensed Species outside the Territory. 

     

    
      	
              ARTICLE
      IV

            

    

    
      	
              PAYMENTS
      AND ROYALTIES

            

    

     

     

    4.01.      Initial
Fee.  On the Effective Date, as an initial license fee, CYTO
shall pay to ABI a sum equal to Thirty Thousand US Dollars
($30,000).  This fee will be wired into ABI’s designated bank account
within 30 days of the Effective Date. Failure to make this initial paymentshall
cause the Agreement to be terminated and to be of no further force or effect
(except for Article XV). Upon  receipt of the initial license fee, ABI
shall provide CYTO with All the existing regulatory documents in ABI’s
possession that are needed to obtain government approval for trials in China and
Taiwan.  ABI shall request HBL transfer the technologies and
manufacturing processes for mixing concentrated IFNα
and ACM to CYTO; and CYTO will utilize such technologies and processes solely
for the purpose of mixing interferon with ACM. After ABI notifies CYTO in
writing or by e-mail of supplying documents above and completes the transfer of
technologies and manufacturing processes, CYTO will wire into ABI’s designated
bank account an additional thirty thousand dollars ($30,000) within 30
days.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

     

    4.02.     Royalty
Payments.  During the TERM, CYTO, its Affiliates or
sub-licensees in bonafide arm’s length transactions, will pay ABI a royalty on
aggregate Net Sales of Product in each calendar year equal to seven and one half
percent (7.5%) each year. Royalties shall be due and payable thirty (30) days
after the end of each calendar quarter (each a “Royalty Payment Date”). CYTO may
prepay, in whole or in part, any royalties prior to the applicable Royalty
Payment Date.  If Other Interferon is formulated with ACM to
manufacture product, Cyto shall pay ABI a royalty on aggregate Net Sales of
Product in each calendar year equal to five and on half percent (5.5%) each
year.

     

    4.03.    Minimum
Royalty. During the TERM, and for each calendar year beginning with the
second calendar year after approval of sales of Product in the Territory, CYTO
shall pay ABI a minimum royalty, which shall be fifty thousand dollars
($50,000).  The Minimum Royalty calculations and payment therefor shall be
made within thirty (30) days after the close of each calendar year, commencing
with the first calendar year after approval of sales of Product in the
Territory.  Failure to make this Minimum Royalty shall be a reason for
Termination pursuant to Section 7.02.  Payments made to ABI pursuant
to Section 4.02 above for the applicable calendar year shall count toward the
Minimum Royalty.

     

    4.04.    Minimum Sales. CYTO shall meet
or exceed the following annual minimum sales.  If CYTO does not
achieve these levels, ABI will have the right to terminate the
Agreement.  Year 1 means the first 12 months after regulatory approval
is obtained.

    Year
1                            $0.5
million

    Year
2                            $1.5
million

    Year 3
and beyond     $4.0 million

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    4.05.      Reports. CYTO
shall furnish to ABI a quarterly written report, which report shall contain at a
minimum (a) the number of interferon and ACM sold; (b) the calculation of Net
Sales; (c) royalties payable in U.S. dollars, if any, which shall have accrued
hereunder based upon Net Sales; (d) withholding taxes, if any, required by law
to be deducted with respect to such sales; (e) the dates of the First Commercial
Sale of any Product; and (f) the exchange rates, if any, used to determine the
amount of United States dollars (collectively, the “Royalty Statement”). Reports
shall be due on the 45th day
following the close of each quarter.

     

     

    4.06.     Records and
Audits.  During the TERM and for a period of two years
thereafter or upon written notice to CYTO received prior to the expiration of
such two year period as otherwise required in order for ABI to comply with
Applicable Law, CYTO shall keep complete and accurate records in sufficient
detail to permit ABI to confirm the completeness and accuracy of the information
presented in each Royalty Statement and all payments due hereunder. CYTO shall
permit an independent, certified public accountant reasonably acceptable to CYTO
to audit and/or inspect those records of CYTO (including financial records) that
relate to number of lozenges sold and Net Sales for the sole purpose of
verifying the completeness and accuracy of the Royalty Statements and, the
calculation of Minimum Royalties, Net Sales and confirming royalty payments for
the Product, during the preceding calendar year. Such inspection shall be
conducted during CYTO’s normal business hours, no more than once in any 12-month
period and upon at least thirty (30) days’ prior written notice by ABI to CYTO.
If such accounting firm concludes that such payments were underpaid during the
periods reviewed by such accountants, CYTO shall pay ABI the amount of any such
underpayments, within thirty (30) days of the date ABI delivers to CYTO such
accounting firm's report so concluding that such payments were
underpaid.  If CYTO

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

     

    fails to
remit the payment within thirty (30) days, interest at a rate equal to the Prime
Rate of Interest shall be imposed starting from the 31st
day.  If such accounting firm concludes that such payments were
overpaid during such period, ABI shall pay to CYTO the amount of any such
overpayments, without interest, within thirty (30) days of the date ABI delivers
to CYTO such accounting firm's report so concluding that such payments were
overpaid. If ABI fails to remit payment within 30 days, interest at a rate equal
to the Prime Rate shall be imposed starting from the 31st
day.  Provisions in this Section 4.06 requiring either Party to pay
interest shall not prevent the other Party from immediately taking all actions
necessary to collect all amounts due, or to enforce any other remedy under this
Agreement.  ABI shall bear the full cost of such audit unless such
audit discloses an underpayment by more than 5% of the amount due during such
period. In such case, CYTO shall bear the full cost of such audit. CYTO shall
provide ABI a copy of the CYTO audited financial statements with sufficient
detail to show the portion of revenue from HBL interferon sales and Other
Interferon formulation with ACM sales each year to be delivered to ABI within 3
months of the end of CYTO’s fiscal year.

     

    4.07.      Exchange Rate; Manner and
Place of Payment.   All payments hereunder shall be payable in
United States dollars. With respect to each calendar quarter, whenever
conversion of payments from any foreign currency shall be required, such
conversion shall be made at the rate of exchange reported in The Wall Street
Journal on the last business day of the applicable calendar quarter. All
payments owed under this Agreement shall be made by wire transfer to a bank
account designated in writing by ABI, unless otherwise specified in writing by
ABI.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    

     

     

    4.08.     Late
Payments. Unless otherwise provided in this Agreement, upon the failure
of CYTO to pay any amount due under this Agreement within five days after
receipt of notice by ABI that such amount has become due and payable and has not
been paid, CYTO shall pay interest to ABI on such amount from the date such
amount is due under this Agreement at the rate of 12% per annum calculated on
the number of days such payment is delinquent, unless such payment is being
disputed by CYTO in good faith pursuant to Section 5.03(a).  Nothing
in this Section 4.08 shall relieve CYTO of CYTO’s obligation to make payments,
risk Termination pursuant to Section 5.03(a), or provide a Royalty Statement
pursuant to Section 5.03(b).

     

    4.09.     Taxes.  All taxes
levied on account of the payments accruing to ABI under this Agreement shall be
paid by ABI for its own account, including taxes levied thereon as income to
ABI. If provision is made in law or regulation for withholding, such tax shall
be deducted from the payment made by CYTO, paid to the proper taxing authority
and a receipt of payment of the tax secured and promptly delivered to ABI.

     

    4.10.             CYTO
shall pay ABI for Bulk HBL Interferon $10/million IU plus $30/kilogram for ACM
plus the amount of any future HBL price increases to ABI.

    

    4.11.             CYTO
shall remit to ABI payment in U.S. funds via wire transfer to a bank account of
ABI’s choice.  Fifty percent (50%) of the payment will accompany the
purchase order with the balance to be paid within 15 days of the date CYTO
accepts delivery at HBL’s factory or warehouse in Japan.

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    ARTICLE
V

    WARRANTIES

     

    ABI makes
no warranty, express or implied, and all implied warranties or warran­ties
of merchantabil­ity and fitness for a particular purpose are hereby
disclaimed and excluded.  HBL warrants to ABI in the HBL Agreement
that Manufactured Products delivered to ABI, its Affiliates, or Sub licensees
shall conform to all specifications listed on the Product Specification Sheet(s)
for said Manufacture Product(s) at the time of its delivery, provided that HBL
shall be compensated separately for any packaging or labeling performed at the
request of ABI.  It is understood that HBL makes no other warranties
of merchantability and fitness for a particular purpose which are beyond the
aforesaid stated warranty obligations are hereby disclaimed and
excluded.

     

                                            ARTICLE
VI

                                    DISCLAIMERS AND
INDEMNIFICATION

     

    6.01.             ABI
makes no represen­tation or warranty that the manufacture or sale of
Manufactured Products will not infringe any third party patent, nor does ABI
assume any obligations with respect to infringements of patents of others
arising as a result of CYTO's activities under this Agree­ment except as
otherwise expressly provided in this Agree­ment.

     

    6.02.             ABI
makes no covenant either to defend any infringe­ment charge by a third party
or to initiate action against infringers of any of its patents except as
otherwise expressly provided in this Agreement.

     

    6.03.             ABI
makes no representation or warranty concern­ing the potential profitability
of sales of Product and shall not be liable for failure of licensee to obtain a
profit or income from such sales.

     

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    6.04.                      
ABI SHALL NOT BE DEEMED TO HAVE MADE ANY REPRESEN­TATION OR WARRANTY AS TO
THE CONDI­TION, MERCHANT­ABILI­TY, DESIGN, FUNCTION OR FITNESS FOR
USE OF PROD­UCTS.

     

    6.05.                      CYTO
agrees that it shall indemnify and save ABI harmless from any and all claims,
demands, actions and causes of action against ABI, whether groundless or not, in
connec­tion with any and all injuries, losses, damages or liabili­ty of
any kind whatsoever, arising, directly or indirect­ly, out of the use,
distribution, and/or sale of Product by or through CYTO.  ABI shall
notify CYTO in writing within ten (10) days of its receipt of any claim, demand
or lawsuit.  Upon assumption by CYTO of its duty to defend, CYTO will
have control of the claim, demand or lawsuit, and except as may be
neces­sary to prevent lapse of its legal rights, ABI shall be required to
incur no expense with regard to said claim, demand or lawsuit.  ABI
shall, at CYTO's request, provide reason­able assis­tance in defense of
any such claim, demand or lawsuit.

     

     

                                            ARTICLE
VII

                                    TERM OR TERMINATION;
DEFAULT

     

    7.01.                      Unless
sooner termi­nated as herein­after provided, this Agreement shall remain
in effect for a period of ten (10) years from the date of this
Agreement.  After said initial term, the Agreement shall be
automatical­ly renewed for successive one (1) year terms subject to the
prior written agreement of the Parties (herein­after called “Renewal
Terms”).

     

    7.02.                      If
CYTO shall at any time during the initial term or any subsequent Renewal Term of
this Agreement default in any obligation hereunder or fail to pay any payment
due, and such default shall not be cured within sixty (60) days after written
notice from ABI to CYTO specifying the nature of the default, ABI may terminate
this Agreement, or may demand specific performance.  Failure
to conduct clinical trials in swine in the USA and China within twelve (12)
months of the execution of this Agreement shall be cause for termination without
notice.

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    7.03.                      If
ABI shall, at any time during the initial term or any subsequent Renewal Terms
of this Agree­ment, default in any obligation hereunder other than a default
caused by HBL and such default shall not be cured within sixty (60) days after
written notice from CYTO to ABI specifying the nature of the default, CYTO may
termi­nate this Agreement, or may demand specific
perfor­mance.  If a default is caused by HBL, ABI will make its
best efforts to influence HBL to cure the default.

     

    7.04.                      Any
termination pursuant to this Article shall not relieve ABI of any obligation to
fill purchase orders placed with ABI prior to termination.

     

    7.05.                      The
exercise by either Party of any right of termina­tion shall not constitute a
waiver of any other rights or remedies available to such party for violation of
the terms of this Agreement or under applicable law.

     

     
ARTICLE VIII

                                                                                
CONFIDENTIALITY

     

    8.01.                      ABI
owns or is licensed under confi­den­tial or secret information relating
to HBL interferon-containing products and the use of same in the Licensed
Species, and it is the intention of ABI to maintain this
confidentiality.

     

    8.02.                      CYTO
possesses trade secrets and technical and marketing information that are
proprietary to CYTO, and it is its intention to maintain the confidentiality of
its propri­etary information.

     

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

    8.03.                      Each
Party agrees to maintain confiden­tial and secret all information which may
be disclosed or provided to it by the other Party and that the Parties may
together subse­quently acquire in relation to interferon-containing products
and which is designated in writing by clearly identifiable legend as being
confidential or secret in character.

     

    8.04.                      Each
Party's obligation to the other (to maintain confidentiality) hereunder shall
terminate with respect to any particular item and only said item of the
disclosing Party's confidential information, when the recipi­ent Party can
demonstrate that such item of information:

     

    8.04.1.                      
Is publicly known and available through some means other than by the recipient
Party's act or omission; or

     

    8.04.2.                      
Was in the recipient Party's pos­session prior to its disclosure by the
other Party, provided that written evidence of such possession is
estab­lished; or

     

    8.04.3.                        Has
come into the recipient Party's possession through a third party free of any
obligation of confidentiality to the disclosing Party, where said third party
has acquired said information lawfully and not under circumstances forbidding
its disclo­sure.

     

    8.05.                      Neither
Party will permit confidential or secret information or any part thereof to be
disclosed to third parties or to employees except on a “need-to-know” basis and
each will maintain confidential or secret informa­tion and/or documents with
the same precautions it uses to safe­guard its own confidential or secret
informa­tion.

     

    8.06.                      Each
Party will notify the other promptly if it has knowledge that a third party
possesses confidential or secret information of the other Party related to
interferon-containing products.

     

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

    8.07.                      CYTO
shall have the right to use ABI's confi­dential or secret informa­tion
to the extent reasonably necessary to accomplish the objectives of this
Agree­ment, including specifically the right to disclose such information to
its Affiliates, actual and potential purchasers or transferees, third-party
contract consultants and scientific investigators (from whom CYTO shall secure
Confidential Disclosure Agreements) and to regulatory agencies in support of
applications for regu­latory agency approval to make, test and/or sell HBL
interferon-­containing products.

     

     

    ARTICLE
IX

    BOOKS
AND RECORDS

     

    9.01.                      CYTO
shall keep proper books of accounts which clearly indicate the volume of sales
and all other financial data and documentation associated with sales of
oral interferon.  CYTO shall provide ABI a copy of the CYTO audited
financial statements with sufficient detail to show the portion of revenue from
sales of Product in Licensed Species each year to be delivered to ABI at the
earliest possible date within 3 months after the end of CYTO’s fiscal
year.

     

    9.02.                      ABI
may nominate an independent public accountant, acceptable to and approved by
CYTO (which approval shall not be unreasonably withheld), once in each calendar
year, to inspect the books of account of CYTO and other records and reports
deemed reasonably necessary for inspection by said accountant during reasonable
business hours for the purpose of verifying the accuracy of the reports and
payments made by CYTO during the preceding calendar year.  Such
accountant shall not disclose any information related to CYTO's financial
matters but shall certify to ABI the accuracy of the reports and payments made
by CYTO in accordance with

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

    this
Agreement.  All fees charged by such accountant shall be paid by ABI
except if there are discrepancies in CYTO's reports, which result in under
reporting or under payment by a factor greater than 10% of the amount
due.  In such instance CYTO shall reimburse ABI for the accountant's
costs other than as required by law.  ABI shall not make any public
disclosure of the CYTO reports or payments referred to in this
agreement.  To the extent disclosure of such information to a third
party is required in the ordinary course of ABI's business, such disclosure
shall be made subject to the recipient's agreement to hold such information in
confidence.

     

     

    ARTICLE
X

    MISCELLANEOUS

     

    10.01.                      Survival.  ARTICLES
VII, VIII, and IX shall survive any termination of this Agreement.

     

    10.02.                      Force Majeure.  The
failure of CYTO, ABI, or any of their Affiliates to take any act re­quired
by this Agreement if occasioned by an act of God or the public enemy, fire,
explosion, earthquake, perils of the sea, floods, drought, war, riot, sabotage,
accident, embargo or any circum­stance of like or different character beyond
the reasonable control of the Party so failing or by the interrup­tion or
delay in transportation, inadequacy, or shortage or failure of the supply of
materials and/or equipment, equipment break­down, labor trouble or
compliance with any order, direction, action  or request of any
govern­mental officer, depart­ment or agency and whether in any case
such circum­stance now exists or hereafter arises, shall not subject either
Party to any liabili­ty to the other.

     

    10.03.                      Arbitration.  The
Parties hereto desire to avoid and settle without litigation future disputes
which may arise between them relative to this Agreement.  Accordingly,
the Parties

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

    agree to
engage in good faith negotiations to resolve any such dispute.  In the
event they are unable to resolve any such dispute by negotia­tion, such
dispute shall be submitted to arbitration as follows: If arbitration is
initiated by CYTO, it shall be held in the State of Texas, U.S.A. in compliance
with the Commer­cial Arbitration Rules of the American Arbitration
Associa­tion.  If arbitration is initiated by ABI, it shall be
held in Taiwan in compliance with the Commer­cial Arbitration Rules of the
Arbitration Associa­tion of Taiwan. The arbitra­tion award shall be
final and binding upon the Parties hereto and may be filed with and enforced by
any competent court of competent jurisdic­tion to enforce said
award.  If arbitration is initiated by ABI for failure to pay for HBL
interferon, Bulk HBL interferon or ACM, it shall be held in Japan in compliance
with the Rule of the Japan Commercial Arbitration Association.

     

    10.04.                      Communication.  Any
payment, notice or other communi­cation required or permitted to be made or
given to either Party hereto pursuant to this Agreement shall be sufficiently
made or given on the date of sending if sent to such Party by certified or
registered mail or by an overnight courier service, postage or delivery charge
prepaid, or by telex or telefax addressed to it at its address set forth, or to
such other address(es) as it may designate by written notice given to the other
Party as follows:

     

    In case of
ABI:                              Dr.
Joseph M. Cummins, Chairman & CEO

    Amarillo
Biosciences, Inc.

    4134
Business Park Drive

    Amarillo,
TX 79110

    Facsimile:
(806) 376-9301

     

    With a copy
to:                            Edward
L. Morris, Legal Counsel

    SandersBaker,
PC

    320 S.
Polk, Ste. 700

    Amarillo,
TX 79101

    Facsimile:
(806) 372-3725

    
      
         

      

      
        18

        
          

        

      

      
         

      

    

     

    In case of
CYTO:                         Dr.
Ellson Chen, Chairman of Board of Directors

    CytoPharm,
Inc.,

    6 F No.
6, Jungshing Road, Sec. 1

    Wugu
Shiang, Taipei County 248

    Taiwan  

    Telephone:
+886-2-89769628

    

                                   
10.05.                      Amendments to
Agreement.  This Agreement consti­tutes the entire
agreement between the Parties hereto with respect to all of the matters herein
addressed, and supersedes all previous arrangements whether written or oral,
covering the same subject matter.  Any amendment or modifica­tion
of this Agreement shall be effective only if made in writing, and executed by
both Parties.

     

    10.06.                      Assignment.  This
Agreement shall not be assignable by CYTO to any person or entity other than a
CYTO Affiliate without the prior written consent of ABI.  This
Agreement shall not be assignable by ABI to any person or entity other than an
ABI Affiliate without the prior written consent of CYTO.

     

    10.07.                      Enforceability.  If
one or more of the provi­sions of this Agreement shall be held to be
invalid, illegal or unenforce­able, the validity, legality or
en­force­ability of the remaining provisions hereof shall not in any way
be affected or impaired thereby.  To the extent permitted by law, each
Party waives any provi­sion of law, which renders any provi­sion herein
invalid, illegal or unenforceable in any respect.

     

    10.08.                      Nature of
Relationship.  Nothing herein shall be construed to place the
Parties in a relationship of partners or joint venturers, nor does this
Agreement make either party the agent or legal representative of the other for
any purposes whatsoever.  The Parties further

    
      
         

      

      
        19

        
          

        

      

      
         

      

    

    agree
that no representation shall be made by either party that would create an
apparent agency, employment, partner­ship or joint
venture.  Neither party shall have the power express or implied, to
obligate or bind the other in any manner what­soever.

     

    10.09.                     
Headings.  The
headings of the several sections of this Agreement are inserted for convenience
of reference only and are not intended to be a part of or to affect the meaning
or interpretation of this Agreement.

     

    10.10.      Waiver.  No
provision of this Agree­ment shall be deemed waived, unless such waiver is
in writing and signed by the Party against which the waiver is sought to be
en­forced.  The waiver by either of the Parties hereto of any
breach of any provision hereof by the other Party shall not be construed to be
either a waiver of any succeeding breach of any such provision or a waiver of
the provision itself.

     

    10.11.        Governmental Approval. In the
event ABI has to obtain the approval from the appropriate govern­mental
authori­ties of Japan to deliver HBL interferon to the country in which CYTO
will use and/or market HBL inter­feron or products containing HBL
interferon, ABI's obliga­tion pertaining to the supply of the said product
to the said country shall be subject to such approval granted in writing to HBL
or ABI.

     

    10.12.             
No Third-Party
Beneficiaries.  This Agreement contemplates no third-party
beneficiaries, and no person or entity, other than the Parties or their
permitted assignees, shall have any rights whatsoever under this
Agreement.

     

    
      
         

      

      
        20

        
          

        

      

      
         

      

    

    IN
WITNESS WHEREOF, the Parties hereunto have caused this Manufactur­ing/Supply
Agree­ment to be executed in dupli­cate by their duly auth­orized
repre­sentatives as of the date first above written.

    ABI:                                                                                             CYTO:

    

    AMARILLO
BIOSCIENCES,
INC.                                                           CYTOPHARM,
INC.

    

    

    

    By:     /s/
Joseph M.
Cummins                                                                  By:     /s/
Ellson Y. Chen

          Dr.
Joseph M.
Cummins                                                                             Dr.
Ellson Y. Chen

          President
and
CEO                                                                                     
Chairman of the Board of Director

    
      
         

      

      
        21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]